Submit your email to push it up the queue
Trio Solutions, LLC, a prominent player in the pharmaceutical consulting industry, is headquartered in the United States. Founded in 2010, the company has established itself as a trusted partner for pharmaceutical and biotech firms, offering specialised services in regulatory affairs, clinical development, and market access strategies. Fulcrum Pharma plc, based in the UK, complements Trio Solutions with its focus on drug development and commercialisation, particularly in the rare disease sector. Established in 2015, Fulcrum Pharma has made significant strides in advancing innovative therapies, leveraging its expertise to navigate complex regulatory landscapes. ADDPLAN GmbH, located in Germany, enhances this collaboration by providing cutting-edge software solutions for clinical trial planning and management. Founded in 2012, ADDPLAN is recognised for its unique approach to optimising trial designs, ensuring efficiency and compliance. Together, these companies form a robust alliance, driving advancements in the pharmaceutical landscape and delivering exceptional value to their clients.
How does Trio Solutions, LLC and Fulcrum Pharma plc and ADDPLAN GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Trio Solutions, LLC and Fulcrum Pharma plc and ADDPLAN GmbH's score of 72 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Trio Solutions, LLC, Fulcrum Pharma plc, and ADDPLAN GmbH, headquartered in the US, currently do not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The organisations are part of a merged entity that cascades its climate commitments and performance data from ICON Public Limited Company, which operates at a cascade level of 2. While there are no documented reduction targets or specific climate pledges from Trio Solutions, Fulcrum Pharma, and ADDPLAN, they are aligned with the broader sustainability initiatives of ICON Public Limited Company. This includes adherence to frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which guide their climate strategies. As part of their commitment to reducing carbon emissions, these organisations are expected to follow the industry standards set by their parent company, focusing on improving sustainability practices and potentially setting future reduction targets. However, specific details regarding their individual commitments or achievements in emissions reduction remain unspecified at this time.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Scope 1 | 1,827,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 18,796,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | 36,726,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Trio Solutions, LLC and Fulcrum Pharma plc and ADDPLAN GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.